Supplementary Figure 4 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment

mTORC1/2 downstream pathway evaluation in Tera cells</p

Supplementary Figure 2 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment

Dasatinib in combination with cisplatin in resistant TC cells</p

Supplementary Figure 3 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment

mTOR knock down in combination with cisplatin in resistant TC cells</p

Supplementary Figure 1 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment

Cisplatin sensitivity in TC cells and RTK validation on western blot</p

Supplementary Figure 7 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment

PDGFRbeta protein expression in TC cell lines</p

Supplementary Figure 6 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment

mTORC1/2 inhibition in combination with cisplatin in TC PDX models</p

Supplementary Figure 5 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment

Autophagy induction and the effect on apoptosis in cisplatin resistant TC cells</p